Home › GenMark Expects 7 Percent Revenue Growth for Q4

GenMark Expects 7 Percent Revenue Growth for Q4

Jan 09, 2018

NEW YORK (GenomeWeb) – GenMark Diagnostics announced today that it expects to post a 7 percent increase its fourth quarter revenues on strong sales of its ePlex molecular diagnostics systems.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Nov
05
Featured Webinar

Overcoming Challenges in Solid Tumor Testing with Advanced AI

Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.

What's Popular?

In Molecular Diagnostics

  1. Roche Patent Invalidation Affirmed in TB Testing Lawsuit Against Cepheid

  2. Liquid Biopsy IDs More NSCLC Mutations, Yields Patient Therapy Response in Study of Guardant Test

  3. Sanofi Genzyme, PerkinElmer Launch Free Dx Program for Patients With Lysosomal Storage Disorders

  4. NanoString Announces $100 Million Term Loan Facility With CR Group

  5. Antibiotic Resistance Monitoring Consortium Expands to Highlight Battle Against Superbugs

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.